SHIFT AI Newsroom · GLOBAL
GLP1 Receptor Agonists Being Investigated for Reducing Side Effects in Lung Cancer Patients
Researchers are exploring the potential of GLP1 receptor agonists to mitigate treatment-related side effects in lung cancer patients receiving lorlatinib.
Researchers are exploring the potential of GLP1 receptor agonists to mitigate treatment-related side effects in lung cancer patients receiving lorlatinib. A new clinical trial has been registered to investigate the impact of using a GLP1 receptor agonist on treatment-related side effects in lung cancer patients receiving lorlatinib.
What this means in the UK
This research may have implications for the management of side effects in lung cancer patients in the UK, potentially improving their quality of life.
Known facts
- A clinical trial has been registered to investigate the impact of using a GLP1 receptor agonist on treatment-related side effects in lung cancer patients receiving lorlatinib.